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Abstract
Objective—To characterize the incidence, management and short term outcomes of
cardiovascular insufficiency (CVI) in mechanically ventilated newborns, evaluating 4 separate
pre-specified definitions.
Study Design—Multicenter, prospective cohort study of infants ≥34 weeks gestational age (GA)
and on mechanical ventilation during the first 72 hours. CVI was prospectively defined as either
(1) mean arterial pressure (MAP) <GA; (2) MAP<GA + signs of inadequate perfusion; (3) any
therapy for CVI; or (4) inotropic therapy. Short term outcomes included death, days on ventilation,
oxygen, and to full feedings and discharge.
Results—Of 647 who met inclusion criteria, 419 (65%) met ≥1 definition of CVI. Of these, 98%
received fluid boluses, 36% inotropes and 17% corticosteroids. Of treated infants, 46% did not
have CVI as defined by a MAP < GA ± signs of inadequate perfusion. Inotrope therapy was
associated with increased mortality (11.1% vs. 1.3%; P < 0.05).
Conclusion—More than half of the infants met at least one definition of CVI. However, almost
half of the treated infants met none of the definitions. Inotropic therapy was associated with
increased mortality. These findings can help guide the design of future studies of CVI in
newborns.
Keywords
blood pressure; cardiovascular insufficiency; mechanical ventilation; inotrope; fluid bolus;
glucocorticoid; outcomes; newborn
INTRODUCTION
Hypotension is commonly diagnosed and treated in mechanically ventilated term and late
preterm newborn infants; however, a specific definition for hypotension in the neonatal
population, its incidence, and its consequences are essentially unknown. Despite an often
unknown etiology and the lack of documented correlation between blood pressure and organ
or tissue perfusion, the diagnosis of hypotension often prompts a cascade of therapies in the
critically ill newborn.1 Volume expanders are usually the first line treatment for newborns
with hypotension, followed by inotropic agents.2 In one large, retrospective study of infants
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>34 weeks gestation, 60% received volume expanders and 35% received inotropes for a
diagnosis of hypotension.3 In addition, glucocorticoids are increasingly used to treat
hypotension in the critically ill term infant.4 The actual frequency of use and outcomes
associated with glucocorticoid administration in this population are currently unknown.
The lack of a clear definition of hypotension and the absence of data regarding incidence,
treatment and associated outcomes in this population significantly impedes the ability to
design rigorous large clinical trials of therapies aimed at treating this condition. Therefore,
we designed a multi-center observational study to address these gaps in knowledge by (1)
characterizing the population of term and late preterm infants receiving mechanical
ventilation for respiratory failure in the first 3 postnatal days, (2) using a broader descriptive
term, cardiovascular insufficiency (CVI), to describe the incidence and treatment approaches
to CVI and (3) evaluating the utility of 4 different definitions of CVI to predict short term
adverse outcomes.
METHODS
We performed a multicenter, prospective, observational cohort study of CVI in critically ill
term and late preterm newborn infants. Infants ≥34 0/7 weeks gestational age admitted to
one of 16 Neonatal Research Network (NRN) centers in 2009 who were intubated and
mechanically ventilated for respiratory failure for at least 1 hour within the first 72 hours
after birth were eligible for inclusion. Infants electively intubated for surgery were excluded,
as were infants with hypotension resulting from documented acute maternal and/or fetal
hemorrhage within 24 hours prior to delivery, and those with a known diagnosis of major
congenital heart disease, moderate or severe hypoxic ischemic encephalopathy (HIE),
pituitary hypoplasia, congenital adrenal hyperplasia, congenital diaphragmatic hernia,
omphalocele or chromosomal disorder.
Clinical data were collected by trained research coordinators, and all analyses were
performed at the Network Data Coordinating Center (RTI International, Research Triangle
Park, NC). Data were entered remotely with electronic submission and scrutinized with
quality control procedures including range checking, internal comparisons for logic
violations and comparison of expected and observed values.
Infant and maternal clinical and demographical data were collected from the medical record.
Data regarding administration of inhaled nitric oxide (iNO), surfactant and/or extracorporeal
membrane oxygenation (ECMO) in the first 72 hours of age were also collected.
Prospectively defined short term outcomes included death, days on mechanical ventilation,
days on oxygen, days to full enteral nipple feedings, and length of stay; these data were
collected at time of death, discharge, transfer, or at 60 days if the infant was still in the
hospital.
Four definitions of CVI were established a priori, as illustrated in Figure 1. Definition A: 2
consecutive mean arterial blood pressures (MAP) lower than the infant's gestational age in
completed weeks at birth. This definition was included because of its presumed prevalent
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use, and because published nomograms have shown that the lower limit of 80% confidence
intervals for MAP is greater than the gestational age in the first 72 hours.5-7
Definition B: definition A plus at least one of the following signs of inadequate perfusion:
capillary refill time >3 seconds, oliguria (urine output <1ml/kg/hour over 6 hours), or serum
bicarbonate <18 and/or base deficit >5. Definition C: receipt of any therapy for CVI,
including fluid bolus, inotropic therapy or glucocorticoid. Definition D: receipt of inotropic
therapy, including dopamine, dobutamine, or epinephrine. The definition of CVI as receipt
of treatment with fluid, steroids or inotropes is based on previously published operational
definitions of hypotension.3,8
For infants who received volume expanders, inotropes or glucocorticoids, data were
collected on age and blood pressure (measured by non-invasive oscillometry and/or
transduced in-line arterial catheters) nearest the time of initiation if available in chart, stated
reason for initiation, dosing, duration and type of therapy. Inotropic drug exposure was
measured as total days of therapy and as peak dose in 6-hour time periods over the first 72
hours of age. The median of 12 (6-hour time blocks × 12= 72 hours) inotrope peak doses
was calculated and then averaged over the first 72 hours of age. The mean peak dose was
calculated by using the following inotropic score, which has been used previously in ill
patient populations9: Dopamine (mcg/kg/min) × 1, plus dobutamine (mcg/kg/min) ×1, plus
epinephrine (mcg/kg/min) × 100, plus phenylephrine (mcg/kg/min) × 100, plus
noradrenaline (mcg/kg/min) × 100.
Waiver of consent was approved by the institutional review boards at 14 NRN sites. At 2
other sites, infants were enrolled after parental written informed consent was obtained.
Statistical Analysis
This study was time-limited to a 9-month enrollment period, was designed to explore the
incidence of CVI in this population and was not hypothesis-driven. However, we calculated
a sample size to test the null hypothesis that <25% of mechanically ventilated newborns
have CVI as defined by receipt of vasopressors/inotropic agents to confirm an estimate of
infants with CVI, based on previous findings.2 At least 494 infants were required to achieve
80% power to detect a difference of 5% (30% of infants given inotropes instead of 25%)
using a 1-sided binomial test with a Type I error rate of 0.05.
Analysis was performed on data that was complete. Three infants were missing fully
completed characteristic data and were not included. Patient characteristics were evaluated
by comparing CVI rates by any definition, by use of any inotrope (definition D), and by no
CVI. Short term outcomes for infants with CVI by any definition and by the definition of
receipt of any inotrope were compared to those without CVI using continuity-adjusted chi-
square test. P values less than 0.05 were considered statistically significant. A priori, sub-
group analysis was planned based on gestational age strata of <37 vs. ≥ 37 weeks.
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RESULTS
Enrollment
During the 9-month study period, 830 infants ≥34 0/7 weeks gestational age at 16 NRN
centers were intubated and mechanically ventilated for respiratory failure for at least 1 hour
during the first 72 postnatal hours. Of these, 183 were subsequently excluded because they
had one or more exclusion criteria (Figure 1). Of the 647 infants included in the analyses,
65% met at least one of the definitions of CVI (Figure 1).
Patient characteristics
Infants with CVI by any definition (N=419) vs. no CVI (N=228) were more mature at birth
(37.3 vs. 36.8 weeks, p=0.008), more likely to be intubated in the delivery room (32% vs.
24%, p=0.045), receive iNO (24.8 % vs. 1.3%, p<0.0001) and/or ECMO (5.7% vs. 0%,
p<0.001), but did not differ in gender, race, ethnicity, rates of prenatal steroid administration
or cesarean section, Apgar scores, receipt of chest compressions or epinephrine in the
delivery room, or outborn vs. inborn status.
Demographics stratified by late preterm and term groups are shown in Table 1, separated
into those with CVI by any definition and those without. Late preterm infants who received
inotropes were more likely to have received intubation (42% vs. 21%, p=0.01) and chest
compressions at delivery (9.8% vs. 2.1%, p=0.04), and more often received iNO (37% vs.
3%, p<0.0001) or ECMO (9.8 %vs. 0.4%, p=0.002) than infants with no CVI by any
definition. Term infants who received inotropes vs. those who did not have CVI by any
definition were more likely to be inborn than outborn (76% vs. 49%,<0.0001), and were
more likely to receive iNO (71% vs. 7.2%, p=<0.0001), surfactant (65% vs. 27%,
p=<0.0001) or ECMO (17% vs. 1.4%, p=<0.0001).
The most common diagnoses recorded in the medical chart included suspected sepsis
(71.1%), respiratory distress syndrome (67.9%), persistent pulmonary hypertension (19.3%),
patent ductus arteriosus (15.9%), pneumothorax or pneumomediastinum (14.7%), meconium
aspiration syndrome (13.9%), and pneumonia (10%).
Incidence of cardiovascular insufficiency and relationship to receipt of therapy
Among included infants, 247 (38%) had CVI by Definition A (2 MAP readings < GA). Of
these infants, 55% (n=135) also had at least one sign of impaired perfusion including
oliguria, metabolic acidosis or poor capillary refill (Definition B). Over half of the study
population (371/647; 57%) met Definition C (fluid infusion, inotrope or steroid therapy). Of
these infants, 36% (n=135) received inotropes (Definition D).
Figure 2 shows the general relationships between these 4 definitions of CVI. Notably, of
infants who received any therapy (Definition C), 46% (172) did not meet either Definition A
or B. As shown in Figure 2, each different definition described a different population –
overlapping but not identical. Only 24 infants (3.7% of 647 enrolled infant) met criteria for
all 4 definitions.
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Therapies received
The fluid most commonly used for volume expansion was normal saline (87.6%), followed
by packed red blood cells (19.3%), and fresh frozen plasma (13.5%). Of 135 infants
receiving inotropic agents, 94.1% received dopamine, 30.4% dobutamine, 25.2%
epinephrine and 3.7% milrinone. Of infants receiving inotropic therapy, 96% also received a
fluid bolus. Of the 64 infants who received steroids, 60 received hydrocortisone and 4
received dexamethasone. Fifty-six (88%) of the infants who received steroids also received
inotropes. Two centers reported no steroid use.
Timing of initiation and duration of therapies
The first dose of any therapy was given at a median age of 5 hours. In the first 7 days of age,
a median [25th percentile - 75th percentile] of 81 [40 - 189] ml/kg of volume boluses was
administered, of which 93% was given in the first 72 hours. Inotropes were received for
median of 2 [1 - 4] days. Over the first 72 hours, the inotrope peak dose in each 6-hour time
period was a median of 5 [2 – 10] mcg/kg/min. For hydrocortisone, the median total dose
given was 7.1 [4- 13.8] mg/kg in the first 72 hours and 13.6 mg/kg [4 - 26] total over a
median of 4 [1 - 8] days. Of the infants treated for CVI, the majority (62%) had a mean
blood pressure >38 mmHg at the time of initial receipt of therapy (mean 41.6 ± 11.2
mmHg).10 The timing and duration of therapies administered and reasons for administering
are stratified by gestational age group in Table 2.
Association with short term outcomes
Infants with CVI by any definition had significantly worse outcomes than those without CVI
except for death in the term infants (Table 3). Those who received an inotropic agent
(Definition D) had a higher incidence of all adverse outcomes than infants who did not have
CVI.
DISCUSSION
In this study of mechanically ventilated term and late preterm infants, we found that a
majority (57%) of these infants were treated for presumed CVI within the first 72 hours.
However, infants with “hypotension” classified by an often-used definition of
MAP<gestational age did not always receive therapy. This suggests that either clinicians are
not aware that infants are meeting this threshold definition or that clinicians take other
factors into consideration when deciding to initiate fluid, inotropic or steroid therapy.
Therefore, blood pressure alone is unlikely to be a useful entry criterion for studies
evaluating therapy for CVI. Conversely, infants who received inotropic therapy had
significantly worse short term outcomes, including a much higher mortality rate, suggesting
that a clinical decision to employ inotropic therapy may define an appropriate high-risk
group for inclusion in future studies.
Our findings are similar to a recent large retrospective study of respiratory failure in late
preterm and term infants.3 Defining CVI as receipt of therapy, Clark reported that of
newborn infants >34 weeks gestation who required mechanical ventilation within 72 hours,
60% received volume expanders and 35% received vasopressors. In our population, 56%
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received volume expanders and 21% received vasopressors. In our study, the most common
treatment pattern began with fluid boluses (predominantly normal saline) followed by
inotropic agents (predominantly dopamine), and subsequently hydrocortisone. This
treatment strategy is similar to the current guideline and recommendations by the American
College of Critical Care Medicine and to the findings of surveys of treatment in preterm
infants.11,12
No blood pressure threshold has been shown to consistently or accurately identify low blood
flow or risk for poor outcomes in this population, nor has treatment of blood pressure been
shown to improve outcomes.6 However, a threshold blood pressure continues to be
frequently used to initiate treatment.12 Surveys suggest that over 25% of neonatologists rely
on blood pressure values alone, and most used a mean blood pressure <GA as the threshold
for therapy.12 In our study, however, 36% of infants with blood pressure <GA received no
therapy, while 46% of those who received therapy did not have a MAP less than gestational
age, suggesting that many neonatologists use other factors in addition to blood pressure to
decide upon treatment. To explore other possible contributing factors, we prospectively
evaluated the use of an additional definition, “low blood pressure and signs of low blood
flow.” Addition of this definition still did not correlate with the decision to institute therapy
or with increased mortality.
We are not aware of any published randomized trials of outcomes following inotrope
therapy in term and late preterm newborns. Observational studies have reported an increased
risk of adverse neurological events and of death in newborns who received vasopressors
compared to those who did not3,13 These increased adverse outcomes could be due to the
underlying disease, inadequate perfusion prior to therapy, the therapy itself, or other factors.
No long term outcome studies have been published to confirm safety or benefit of any
inotrope in neonates.
Furthermore, there have been no randomized controlled trials of glucocorticoid therapy to
treat or prevent CVI in term and late preterm infants. The few trials in preterm infants have
shown improved blood pressure, decreased administration of vasopressors, reduced days on
vasopressors and decreased use of volume therapy compared to placebo.14,15 Despite this
lack of information for term infants, clinicians in 14 of the 16 study centers administered
steroids for the treatment of hypotension.
This study was intentionally limited in its scope. Although a power analysis was performed
to ensure adequate numbers were enrolled to confirm the incidence of hypotension, this was
not a hypothesis-driven study for comparisons between groups. We did not analyze
differences between blood pressures measurements by oscillatory vs. arterial line methods;
however, a recent report found good agreement between these two methods.16 This study
also did not collect data on the utilization of newer modalities for determining blood flow
and perfusion, such as near-infrared spectroscopy (NIRS) or bedside functional
echocardiogram.17,18 in the future, such tools may help evaluate the contributions of
underlying diseases, clinical factors, and treatments to outcomes in this population.
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In conclusion, more than half of the mechanically ventilated term and late preterm infants in
this study received therapy for suspected CVI. At the same time, many who met a widely
used definition of CVI (mean BP <GA) were not treated, and many treated infants did not
have a mean BP<GA or documented signs of low systemic blood flow. Receipt of inotropic
therapy appeared to define the highest risk group. The results of this study will inform the
design of future randomized controlled trials of treatment(s) for cardiovascular insufficiency
in these critically ill patients.
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Figure 1.
*Clinical sign: poor capillary refill (>3 seconds), oliguria (urine output <1ml/kg/hour over 6
hours) or serum bicarbonate <18 and/or base deficit >5
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Figure 2.
Percent (%) is number of infants with the each definition divided by total number of infants
enrolled. Of the 112 infants who met criteria for Definition A, 36% (40) received no
therapy. Of those who met either Definition A or B (low mean blood pressure ± clinical
signs of low blood flow), 19% (48) were not treated. Of infants who received inotropic
agents (Definition D), 30% (40) did not have CVI by Definition A and 47% (64) did not
meet Definition B. Of the infants who received fluid expansion, 46% (166) did not have CVI
by Definition A and 65% (237) did not meet definition B.
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Table 3
Short term outcomes, stratified by gestational age, median (interquartile range)
All infants No CVI CVI By any definition Received inotrope* P value†
GA < 37 weeks n = 277 n = 115 n = 162 n = 42
Death 3% 0% 6% 14%* 0.03
Days of age at death 9 (4, 16) NA 9 (4, 16) 4 (3, 16) NA
Days intubated and on mechanical ventilator 2 (2, 5) 2 (2, 4) 3 (2, 7) 7 (4, 11)* 0.0001
Days on oxygen 5 (2, 9) 4 (2, 8) 6 (3, 11) 11 (4, 16)* 0.03
Days of age at time of full nipple feeding 9 (6, 17) 8 (6, 14) 12.5 (7, 21) 21 (10, 27)* 0.001
Days in NICU 12 (8, 25) 10 (6, 17) 15 (9, 29) 16 (10, 34)* 0.001
GA ≥ 37 weeks n = 370 n = 113 n = 257 n = 93
Death 4% 3% 5% 10* 0.44
Days of age at death 13 (2, 46) 48 (30, 60) 10 (2, 18) 12 (2, 18)* 0.10
Days intubated and on mechanical ventilator 3 (2, 8) 2 (1, 4) 4 (2, 10) 10 (4, 13)* <.0001
Days on oxygen 5 (2, 10) 3 (1, 5) 7 (2, 13) 11 (8, 19)* <.0001
Days of age at time of full nipple feeding 8 (5, 15) 6 (3, 9) 10 (6, 17) 14 (10, 26)* <.0001
Days in NICU 12 (7, 21) 8 (5, 15) 14 (8, 24) 17 (11, 35)* <.0001
CVI cardiovascular insufficiency; NICU Newborn intensive care unit; GA gestational age
*Significant at P<0.05 vs. no CVI
†
P value for CVI by any study definition vs. no CVI
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